Neogen Corporation (NEOG) Insider Trading

Last 12 months

Insiders bought $14k on the open market and sold nothing.

Net open-market

+$14k

6 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

1 / 0

executives and directors

Last open-market buy

Oct 2026

Oct 9, 2026

Get an email when NEOG's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 9	Mikheal Nassif CEO	Bought	505	$11.95	$6k	47%	Form 4
Aug 4	Mikheal Nassif CEO	Bought	370	$11.81	$4k	53%	Form 4
Feb 17	Mikheal Nassif CEO	Bought	23	$10.94	$252	3.4%	Form 4
Jan 26 – Feb 2	Mikheal Nassif CEO	Bought 2 parts	49	$9.93 average	$487	7.8%	Form 4
Jan 16	Mikheal Nassif CEO	Bought	137	$9.33	$1k	28%	Form 4
Nov 3, 2025	Mikheal Nassif CEO	Bought	177	$6.25	$1k	56%	Form 4
May 12, 2025	Aashima Gupta Director	Bought	16,000	$6.25	$100k	270%	Form 4
Apr 25, 2025	Catherine E Woteki Director	Bought	5,770	$5.17	$30k	77%	Form 4
Apr 24, 2025	James C Borel Director	Bought	30,000	$4.99	$150k	50%	Form 4
Apr 24, 2025	William T Boehm Director	Bought	5,000	$5.24	$26k	16%	Form 4
Apr 24, 2025	James C Borel Director	Bought	35,000	$4.89	$171k	137%	Form 4
Apr 23, 2025	Amy M Rocklin Chief Legal Officer	Bought	12,500	$4.99	$62k	53%	Form 4
Apr 22, 2025	Jeffrey D Capello Director	Bought	20,712	$4.84	$100k	350%	Form 4
Apr 22, 2025	James P Tobin Director	Bought	10,000	$4.73	$47k	36%	Form 4
Apr 22, 2025	Rafael A Rodriguez Director	Bought	7,474	$4.59	$34k	100%	Form 4
Apr 10, 2025	John Patrick Moylan Chief Accounting Officer	Bought	10,000	$5.07	$51k	New	Form 4
Jan 16, 2025	David H. Naemura CFO	Bought	14,800	$11.11	$164k	32%	Form 4
Jan 16, 2025	John Edward Adent CEO	Bought	23,035	$11.03	$254k	9.4%	Form 4

Oct 9
Mikheal Nassif
CEO · bought 505 at $11.95
$6k
47% of stake
Aug 4
Mikheal Nassif
CEO · bought 370 at $11.81
$4k
53% of stake
Feb 17
Mikheal Nassif
CEO · bought 23 at $10.94
$252
3.4% of stake
Jan 26 – Feb 2
Mikheal Nassif
CEO · bought 49 at avg $9.93
$487
7.8% of stake
Jan 16
Mikheal Nassif
CEO · bought 137 at $9.33
$1k
28% of stake
Nov 3, 2025
Mikheal Nassif
CEO · bought 177 at $6.25
$1k
56% of stake
May 12, 2025
Aashima Gupta
Director · bought 16,000 at $6.25
$100k
270% of stake
Apr 25, 2025
Catherine E Woteki
Director · bought 5,770 at $5.17
$30k
77% of stake
Apr 24, 2025
James C Borel
Director · bought 30,000 at $4.99
$150k
50% of stake
Apr 24, 2025
William T Boehm
Director · bought 5,000 at $5.24
$26k
16% of stake
Apr 24, 2025
James C Borel
Director · bought 35,000 at $4.89
$171k
137% of stake
Apr 23, 2025
Amy M Rocklin
Chief Legal Officer · bought 12,500 at $4.99
$62k
53% of stake
Apr 22, 2025
Jeffrey D Capello
Director · bought 20,712 at $4.84
$100k
350% of stake
Apr 22, 2025
James P Tobin
Director · bought 10,000 at $4.73
$47k
36% of stake
Apr 22, 2025
Rafael A Rodriguez
Director · bought 7,474 at $4.59
$34k
100% of stake
Apr 10, 2025
John Patrick Moylan
Chief Accounting Officer · bought 10,000 at $5.07
$51k
New position
Jan 16, 2025
David H. Naemura
CFO · bought 14,800 at $11.11
$164k
32% of stake
Jan 16, 2025
John Edward Adent
CEO · bought 23,035 at $11.03
$254k
9.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NEOG, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: In Vitro & In Vivo Diagnostic Substances

MYGNMyriad Genetics Inc.

LNTHLantheus Holdings, Inc.

QDELQuidelOrtho Corporation

IDXXIDEXX Laboratories, Inc.

IONSIonis Pharmaceuticals, Inc.

USNAUsana Health Sciences, Inc.

CORTCorcept Therapeutics Incorporated

SUPNSupernus Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in NEOG's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NEOG

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.